{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007864","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.670815+00:00","generated_at":"2026-06-18T03:40:34.768485+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Design Therapeutics Q4 net loss $17.3M; FY2022 net loss $63.3M; cash $330M; DT-216 MAD data mid-2023","bullets":["R&D expenses $14.3M (Q4) and $48.6M (FY2022); G&A $5.1M (Q4) and $19.0M (FY2022).","Cash, equivalents and securities $330.4M as of Dec 31, 2022; expected runway through 2025.","Phase 1 MAD trial of DT-216 for Friedreich Ataxia ongoing; initial data expected mid-2023, final by year-end.","IND submission for DT-168 (FECD) planned H2 2023; DM1 program targeting IND in 2024.","No revenue reported; net loss driven by R&D investment in clinical and preclinical pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007864","json":"https://secwatch.observer/filing/0000950170-23-007864.json","markdown":"https://secwatch.observer/filing/0000950170-23-007864.md","text":"https://secwatch.observer/filing/0000950170-23-007864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023007864/0000950170-23-007864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023007864/dsgn-20230314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T03:40:34.768485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67b9c49f70e10e35837313dd3dc1903ae8811b70","claim":"Design Therapeutics, Inc. reported three and twelve months ended December 31, 2022 results: net income Net loss was $17.3 million for the quarter ended December 31, 2022, and $63.3 million for the year ended December 31, 20.","evidence_excerpt":"On March 14, 2023, Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023007864/0000950170-23-007864-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and twelve months ended December 31, 2022"},{"label":"Net income","value":"Net loss was $17.3 million for the quarter ended December 31, 2022, and $63.3 million for the year ended December 31, 20"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}